High-Rebound Cushioning Knitted Upper

Q1: What is the target energy return percentage (e.g., ≥60%, ≥75%) you need from the shoe upper under dynamic loading?

A: Please specify the required rebound efficiency to optimize the elastomeric yarn composition and knit structure.

Q2: What is the expected cushioning performance retention period under daily wear and wash cycles?

A: Define the required service life of the shock-absorbing function to guide the selection of foam additives and loop geometry.

Q3: Do you have specific test standards for validating rebound performance (e.g., ASTM F1976, ISO 20344 section 8.9, SATRA TM142)?

A: List all mandatory laboratory test protocols to confirm the impact attenuation and energy storage of the product.

Q4: What is the maximum peak deceleration (g‑force) you permit for the fabric at a 50‑joule impact (e.g., ≤15g, ≤20g)?

A: Provide clear quantitative benchmarks for shock mitigation to match your athletic or industrial footwear requirements.

Q5: Are there restrictions on the type of resilient materials used (e.g., TPU elastomers, EVA foam microbeads, latex rubber, polyolefin)?

A: Provide a detailed list of allowed, restricted, or prohibited active substances for the cushioning treatment.

Q6: How should the high-rebound feature be presented on product tags, packaging, or promotional materials (e.g., energy-return icon, g‑force rating, rebound percentage)?

A: Explain your requirements for labeling, consumer communication, and brand messaging related to the cushioning function.

Q7: What is your target timeline from the technical approval of the rebound sample to the first commercial delivery?

A: Share your product development and launch schedule to align our production and collaboration efforts.

Q8: Should the cushioning treatment be applied to the entire upper, only the heel and forefoot zones, or specific high-impact areas (heel strike, toe-off)?

A: Clarify the treatment scope to balance cost efficiency, functional effectiveness, and wearing flexibility.

Q9: What are your projected order quantities for the initial production run and expected reorders within the first 18 months?

A: Provide demand forecasts to support the procurement of high-elasticity yarns and production scheduling.

Q10: What are your standard commercial terms, including payment method, deposit percentage, and balance payment schedule?

A: Advise us of your standard payment structure and cooperation terms for new suppliers.

Q11: Will this upper be combined with other functional treatments (e.g., antimicrobial, waterproof, abrasion-resistant)? If yes, please specify the performance priority.

A: Inform us of any additional treatments to ensure chemical compatibility and process feasibility.

Q12: Are there specific regional safety compliance rules we must follow (e.g., EU EN ISO 20344, US ASTM F2413, China GB/T 20991) for cushioned footwear materials?

A: List the key regulatory markets to ensure full compliance of the rebound treatment and materials.

Q13: What is your internal approval process for functional performance test reports and aesthetic sample assessments?

A: Outline the stakeholders, review steps, and approval criteria for both laboratory data and physical samples.

Q14: Do you have preferred suppliers for high-rebound masterbatch or thermoplastic elastomers, or should we suggest our qualified partners?

A: Indicate whether you have an approved vendor list for functional raw materials or if we can propose reliable suppliers.

Q15: What is the maximum acceptable cost increase for adding the cushioning functionality compared to a standard knitted upper?

A: Provide a target cost range or acceptable percentage markup to guide material and treatment selection.

Q16: What key physical tests (other than rebound performance) are mandatory for the final upper (e.g., tensile strength, flex resistance, colorfastness to sweat)?

A: Detail all additional quality and performance tests required for product acceptance.

Q17: Are there any specific shoe assembly methods (e.g., cementing, direct injection, heat molding) that could impact the cushioning treatment's effectiveness?

A: Inform us of the shoe assembly process to assess potential thermal or compression risks to the rebound layer.

Q18: What is your target gram weight for the finished knitted fabric, and does the cushioning treatment usually add weight that needs to be considered in design?

A: Specify the target fabric weight to ensure the final product meets your design and performance standards.

Q19: How do you plan to validate the consumer-perceived benefit of the rebound feature (e.g., treadmill gait analysis, impact hammer test, wearer fatigue survey)?

A: Describe any planned testing methods, as they may influence our treatment level suggestions.

Q20: What are your preferred shipping Incoterms, main destination ports, and average expected transit time from our factory?

A: Confirm logistics terms, primary delivery points, and timing expectations for order fulfillment.

Q21: Do you require the knitted fabric to retain its stretch recovery and breathability after the cushioning treatment?

A: Specify your expectations for fabric handfeel and wearing comfort after functional processing.

Q22: Are there special requirements for color consistency in mass production of the high-rebound knitted upper?

A: Explain your standards for color uniformity and batch-to-batch consistency in bulk production.

Q23: Do you require the cushioning function to remain effective at different temperatures (e.g., –10°C winter, 40°C summer)?

A: Clarify if the rebound performance needs to be stable under thermal extremes for all‑weather footwear.

Q24: What is your acceptable elongation rate for the knitted fabric after washing, and does the cushioning treatment affect elongation?

A: Define the maximum allowable elongation rate and confirm if the treatment needs adjustment to meet this requirement.

Q25: Are there any requirements for the fabric's hysteresis loss (energy dissipation) to complement the rebound function?

A: Specify the target hysteresis value to ensure optimal return efficiency and walking economy.

Q26: Do you require customized packaging (e.g., compressed rolls, moisture‑barrier pouches, brand-embossed) for the finished uppers?

A: Specify your packaging requirements to protect the cushioning function during storage and transportation.

Q27: Will the upper be used in orthopedic or diabetic footwear? If so, are there additional pressure‑redistribution requirements for the rebound treatment?

A: Indicate if the product is for medical use and provide any special pressure‑mapping standards.

Q28: What is your expected lead time for sample production and delivery after confirming functional requirements?

A: Share your sample delivery timeline expectations to arrange our sample production schedule.

Q29: Do you require the cushioning treatment to be non‑irritating and suitable for users with sensitive skin?

A: Clarify if the treatment needs to meet specific dermatological test standards for sensitive users.

Q30: Are there any requirements for the rebound materials to be non‑toxic and compatible with food‑grade or children's footwear applications?

A: Specify your expectations for the toxicity level and compatibility of the cushioning ingredients and materials.

For a customized quotation or to schedule a technical discussion on integrating effective high‑rebound solutions into your footwear line, please contact our functional materials team. We are ready to partner on developing products that prioritize impact protection, energy return, and lasting walking comfort.